Pricing
Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026)
Microdose programmes in our July records ran $110 to $349 a month; NexLife’s microdose plans now cost $129 month to month or $115 on twelve months (read November 8, 2026). They deliver roughly 1 mg weekly against the 5, 1
Microdose programmes in our July records ran $110 to $349 a month; NexLife’s microdose plans now cost $129 month to month or $115 on twelve months (read November 8, 2026). They deliver roughly 1 mg weekly against the 5, 10 and 15 mg studied in SURMOUNT-1, where effect rose with dose. No trial has measured a microdose, so this is a lower-dose treatment rather than a cheaper route to the same result.
Read this before the price table
A microdose programme is not a discount tier of a standard programme. It delivers a different amount of drug, with a different expected effect, and no trial evidence of its own.
SURMOUNT-1 reported mean weight reduction of about 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, against 3.1% with placebo. The relationship is clean: more dose, more effect.
A roughly 1 mg weekly dose sits below every dose tested. Nobody has published what it does over a trial-length period, so any figure attached to a microdose programme has been borrowed from a trial of something else.
The prices
Captured by us: NexLife (opens nexlife.us in a new tab) at $115 a month on a twelve-month plan and $129 month-to-month, flat at every covered dose, no membership fee, read from its own plan pages on 11 July 2026.
Provider-reported: Enhance.MD at $169 for a stated 1 mg weekly programme including lab testing, delivered twelve-weekly. Shed at $199 with a two-month minimum. Gala for microdosing. bmiMD at $349, which is above most competitors' standard injectable pricing.
Compounded semaglutide microdose programmes start lower, at $110 a month.
What the saving actually is
Within the same provider, a microdose typically saves $30 to $110 a month against the standard programme. NexLife: $115 against $115 since November 2026. Enhance.MD: $169 against $280. Shed: $199 against $245. bmiMD is the outlier at $349 against $399.
So the question is not whether it is cheaper. It is whether the lower dose does what you need — a clinical question with no published answer at that dose.
The comparison that reframes it
The cheapest FDA-approved GLP-1 of any kind is $149 a month at its starting dose, with published trial data, FDA review and manufacturer supply. Two microdose programmes in our dataset cost more than that.
Eligible Medicare enrollees pay $50 through the GLP-1 Bridge, and a covered brand can land near $25. Both are below every microdose programme here, for an approved product at a studied dose.
Why the category exists
Partly clinical and partly regulatory, and it is worth separating the two.
Clinically, prescribers reduce doses for real reasons: side-effect burden, comorbidities, patient preference, or maintenance after a period at a full dose. A patient who cannot tolerate 10 mg is better served at 5 than at nothing, and the label's titration is explicitly tolerability-driven.
Regulatorily, compounding a copy of an available approved product is generally not permitted. Compounding something a prescriber documents as clinically different for an individual patient is. That documentation requirement is what “personalised dosing” satisfies.
This explains the timing better than any clinical development does: the microdose category expanded when the shortage listings ended, not when new evidence appeared.
The maintenance argument, examined
The strongest case for low-dose therapy is maintenance — someone who reached a target on a full dose, then reduces to hold it. That is a recognised pattern in other chronic conditions.
The gap is that it has not been tested here. SURMOUNT-4 studied continuation at maximum tolerated dose against complete withdrawal. It did not study reduction to a low dose, which is the intermediate option the maintenance argument depends on.
A provider offering microdosing as maintenance is therefore extrapolating from a trial that tested something else. That may still be sound clinical judgement for an individual patient — but it is judgement, not evidence, and it should be described that way.
Four questions before enrolling
- What weekly dose does this deliver, in milligrams? A programme that will not answer cannot be compared with anything, including itself over time.
- What evidence exists for that dose specifically?
- Is the plan to escalate, and does the price change if I do?
- If this is maintenance dosing, what was I meant to have done first?
The price board
Lowest all-in price per program
The lowest monthly figure each of the 33 programs in our price index prints for standard compounded tirzepatide, sorted low to high. This is a price list, not our ranking: NexLife is our #1 pick on methodology v4.1, and three programs list a lower figure than its $115 12-month rate. 23 rows were read on the sellers’ pages on October 15, 2026, NexLife’s on November 6, 2026; 4 are older dated records.
| Measure | What the plan pages say |
|---|---|
| Compounded tirzepatide | $129 a month month to month; $125, $119 or $115 a month on 3-, 6- or 12-month plans |
| 12-month plan, year total | $1,380 ($115 × 12) |
| Compounded semaglutide | $109 a month month to month; $105, $99 or $95 a month on 3-, 6- or 12-month plans |
| Price at higher doses | The same at every dose |
| Membership fee | None |
| Pharmacies named | Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA); all state-licensed 503A |
| Cancellation | Takes effect after 30 days, so one more shipment may be charged |
| Methodology score | 94 of 100 (v4.1), ranked first |
| Measure | Standing | Why | Status |
|---|---|---|---|
| Cheapest advertised entry price | No | Several providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does. | Provider-reported Reported |
| Names its fulfilling pharmacy | No | States 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here. | Pending Pending |
| Trial figure on its own site | Queried | Its page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5% (efficacy estimand). We have asked for a correction. See COR-007. | Pending Pending |
| Development | What happened | Status |
|---|---|---|
| Tirzepatide shortage resolved | Declared resolved 2 October 2024, which ended the shortage basis for compounding | Verified Verified |
| 503B bulks proposal | FDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026 | Verified Verified |
| Brand direct pricing | Zepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only route | Verified Verified |
| Compounding additives | A 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drug | Verified Verified |
| Hims and tirzepatide | Reported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed it | Third-party claim Pending |
| Litigation volume | Novo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide side | Provider-reported Reported |
| Measure | Figure | What it measures | Source |
|---|---|---|---|
| Efficacy estimand, 15 mg | 22.5% (efficacy estimand) Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 10 mg | 21.4% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 5 mg | 16.0% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Treatment-regimen estimand, 15 mg | 20.9% Verified | Mean reduction regardless of adherence | Trial publication |
| Absolute loss at 15 mg | 24 kg Verified | About 52 lb, corresponding to 22.5% (efficacy estimand) | Manufacturer announcement |
| Median time to weight plateau | 24.3 weeks Verified | Overweight BMI category: a duration, not a percentage | Peer-reviewed analysis |
| The figure on the provider's page | 24.3% Outdated | Stated as body-weight reduction in SURMOUNT-1 | Provider's own page |
| Provider | Lowest reported | Highest reported | Spread | Publishers | What the gap actually is |
|---|---|---|---|---|---|
| Found | $169 | $497 | $328 | 2 | 12-month prepaid against membership-plus-medication total |
| bmiMD | $139 | $399 | $260 | 2 | 12-month tier against standard ongoing rate |
| Oak Longevity | — | — | — | 2 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| Enhance.MD | $99 | $280 | $181 | 1 | First-month promotional rate against ongoing standard |
| Shed | $199 | $424 | $225 | 1 | Microdose against brand Zepbound plus membership |
| Henry Meds | — | — | — | 6 | Every figure withdrawn 27 July as an unconfirmed third-party claim, COR-009 |
| SkinnyRx | — | — | — | 1 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| TrimRx | $179 | $259 | $80 | 2 | Reported flat against a 12-month commitment tier |
| Mochi Health | $278 | $278 | $0 | 3 | Three publishers agree — membership plus medication |
| NexLife (opens nexlife.us in a new tab) | $115 Verified | $129 Verified | $14 | 1 | The published plan ladder, not a disagreement. Same price at every dose |
A dash means no figure held. How we grade evidence.
| Programme | Monthly | Term | Evidence |
|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) microdose | $115 Verified | 12-month plan | Verified Verified |
| NexLife (opens nexlife.us in a new tab) microdose | $129 Verified | Month-to-month | Verified Verified |
| Gala GLP-1 | — | Withdrawn: third-party claim | Third-party claim Pending |
| Enhance.MD | $169 | 12-month plan, $99 first month | Provider-reported Reported |
| Shed | $199 | 12-month plan | Provider-reported Reported |
| bmiMD | $349 | Not stated | Provider-reported Reported |
A dash means no figure held. How we grade evidence.
| Provider | Advertised | What the figure describes | Price at a maintenance dose |
|---|---|---|---|
| Embody | — | Withdrawn: third-party claim, see COR-008 | — |
| SkinnyRx | — | Withdrawn: third-party claim | — |
| Lavender Sky Health | — | Withdrawn: third-party claim | — |
| Oak Longevity | — | Withdrawn: third-party claim | — |
| Fifty 410 | — | Withdrawn: third-party claim | — |
| Yucca Health | — | Withdrawn: third-party claim | — |
| TrimRx | about $179 | Reported monthly figure | — |
| Henry Meds | — | Withdrawn 27 July as an unconfirmed third-party claim, COR-009 | — |
| NexLife (opens nexlife.us in a new tab) | $115 to $129 Verified | Flat across covered doses, no membership | $115 to $129 Verified |
| OrderlyMeds | — | No obtainable published figure | — |
A dash means no figure held. How we grade evidence.
| Mechanism | What it does | Who does it, in our dataset |
|---|---|---|
| Membership stacking | A separate required fee on top of medication | PlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149 |
| Dose-escalation pricing | Price rises as the dose is titrated up | LillyDirect $299→$449 · Shed · MEDVi reported to $499 |
| Introductory rate | A first-month price that reverts | 11 programmes; all excluded from every ranking here |
| Prepayment requirement | Lowest rate needs a full term upfront | Found $169 prepaid vs $289 monthly (71%) · NexLife (opens nexlife.us in a new tab) $115 vs $129 (12%) |
| Undisclosed inclusions | Labs, in particular, frequently unstated | Not captured for most providers Pending |
| Publisher | Figure published | What it appears to describe |
|---|---|---|
| GLP-1 Editorial | $369/mo These Henry Meds figures were taken from third-party publications and are withdrawn pending a capture of our own; see COR-009. | Starting and maintenance, described as flat |
| RxPepsDirect | $179/mo | Flat all-inclusive bundle: medication, visits, supplies, shipping |
| Forbes Health | from $297/mo | Oral tirzepatide tablets |
| Forbes Health, pricing table | from $179/mo | Compounded medication cost |
| RangeYourself | $179/mo | All-in, medication included |
| This publication | Provider-reported Reported | We hold a provider-reported figure and no capture of our own |
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $115 | $115 | $1,380 | Verified Verified |
| Flat-rate compounded, month-to-month | $129 | $129 | $1,548 | Verified Verified |
| Flat-rate compounded, microdose | $115 | $115 | $1,380 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,188 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Reported |
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $115 | — | — | — |
| Found — compounded injectable | $169 | — | — | — |
| Enhance.MD — compounded microdose | $169 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $115 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $129 | $129 Pending | $1,548 Pending | Flat at every dose Reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $119 | $119 Verified | $1,428 Pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $125 | $125 Verified | $1,500 Pending | Flat at every dose Verified |
| Shed — compounded microdose | $199 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | — | — | — |
| NexLife — compounded injectable | $129 | $129 Verified | $1,548 Pending | Flat at every dose Verified |
| Shed — compounded injectable | $245 | — | — | — |
| Mochi Health — compounded injectable | $278 | — | — | — |
| Enhance.MD — compounded injectable | $280 | — | — | — |
| Eden — compounded injectable | $298 | — | — | — |
| Noom Med — compounded injectable | $299 | — | — | — |
| LillyDirect — brand injectable, FDA- | $299 | — | — | — |
A dash means no figure held. How we grade evidence.
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $1,380 | Verified |
| Flat compounded, month-to-month | $1,548 | Reported |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,188 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Reported |
| Price type | Meaning |
|---|---|
| Recurring | The ongoing monthly rate with no term commitment |
| Commitment tier | Requires a multi-month term, often paid upfront |
| Limited-time promo | A time-limited offer that will revert |
| Advertised starting price | A 'from' or 'starting at' figure, usually the entry dose |
| Range | Provider publishes a band rather than a single figure |
| Membership plus medication | Two charges; the all-in figure combines them |
| Intake-gated | No obtainable public price |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Questions readers actually ask
What is the cheapest microdose tirzepatide?
From its plan pages read November 8, 2026: NexLife at $115 a month on a twelve-month plan and $129 month to month. Provider-reported programmes range from $149 to $349.
Does microdose tirzepatide work?
No trial has measured a roughly 1 mg weekly dose over a trial-length period. SURMOUNT-1's dose-response data suggests less effect than the studied doses produced.
Is microdosing cheaper than standard dosing?
Within the same provider, typically $30 to $110 a month less. It is also a lower dose with a smaller expected effect, so it is not a discount on the same treatment.
Why do microdose programmes exist?
Partly clinical, and partly because documenting a clinical difference for an individual patient is one of the surviving routes for compounding when an approved product is available.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Tirzepatide Price by DosePillar / Money
- How Dose Escalation Changes Tirzepatide CostJournal
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Flat-Rate vs Dose-Escalating GLP-1 PricingComparisons
- Flat-Rate Tirzepatide Pricing ComparedPillar / Money
- Why Multi-Dose Vials Create Tirzepatide Dosing ErrorsJournal
Related coverage
- Microdose Tirzepatide: Evidence, Cost and Limitations
- Programmes that hold price at every dose
- Compounded tirzepatide price index
- What you pay at a maintenance dose
- Provider Ranking Methodology
- Missing a GLP-1 Dose: What the Label Says and What to Ask
- Most Affordable Tirzepatide Online: Verified All-In Costs
- Mounjaro for Weight Loss: The Same Molecule at Three Times the Price
- GLP-1 and Tirzepatide News
Tirzepatide Ranked. “Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026).” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/microdose-tirzepatide/cheapest/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.